Vilon20mg
Vilon Canada — 20 mg Lyophilized Vials
Peptide Bioregulator
Also known as Lys-Glu (KE)
Vilon is the dipeptide Lys-Glu, one of the most extensively studied short peptide bioregulators, examined in research on chromatin activation and immune endpoints.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Vilon is the dipeptide Lys-Glu, one of the most extensively studied short peptide bioregulators, examined in research on chromatin activation and immune endpoints.
Experimental models span lymphocyte cultures from older donors, gene-expression profiling, and tumour-induction studies in rodents.
Vilon is a two-residue peptide with an unusually broad literature for its size. Published work has reported reactivation of chromatin in cultured lymphocytes from older people, effects on gene expression in mouse heart characterized by DNA microarray, and modulation of gene expression in ageing mesenchymal stem cell cultures.
Separate research examined signal transduction along the sphingomyelin pathway in thymocytes, and the peptide appears throughout reviews of short-peptide epigenetic regulation.
Vilon was among the first synthetic short peptides characterized in the Russian bioregulator programme, developed as a defined analogue of thymic peptide preparations.
Work from the late 1990s onward established it as the reference compound for the class, frequently used as a comparator against Epitalon.
Research into the Lys-Glu dipeptide focuses on chromatin reactivation in ageing cells and on gene-expression regulation. Frameworks evaluate heterochromatin decondensation, microarray transcriptional profiles, sphingomyelin-pathway signaling, and immune endpoints under controlled in vitro and preclinical conditions.
3 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Lezhava 2004. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Anisimov 2002, Ashapkin 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Khavinson 2002. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on immune, gerontology or endpoint. This heading marks where Vilon is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 5 primary papers published between 2002 and 2020 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Vilon, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Vilon is commonly described online in connection with slowing ageing and extending lifespan. In the research literature the same compound is filed under chromatin reactivation in ageing lymphocytes, microarray gene-expression profiling and sphingomyelin-pathway signal transduction.
The 5 papers cited on this page, published between 2002 and 2020 (1 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for Vilon is per lot, not per product. The current 20mg lot VILO-CA-26H-20 returned 99.91% purity, 23.29 mg measured, 116.4% of the labelled 20 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is Vilon; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for Vilon, this lot measured 116.4% of its labelled 20 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for Vilon. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy Vilon in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
Vilon is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 2 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of Vilon. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people
PubMedStudies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology
PubMedEffects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway
PubMedGene expression in human mesenchymal stem cell aging cultures: modulation by short peptides
PubMedRelated
Eppix Flash Sale −30%Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$41.96$59.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$24.46$34.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$38.46$54.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$101.46$144.95CAD
Flash sale ends in
